The U.S. Food and Drug administration has approved the use of Roche’s  Actemra/RoActemra (tocilizumab) subcutaneous injection for Giant cell arteritis(GCA), a severe autoimmune disease which affects nearly 280,000 people in U.S. every year. What is Giant cell arteritis? Giant cell arteritis is a severe autoimmune condition which mostly affect people above 50 years of age. […]

The post Giant Cell Arteritis gets its first Fda Approved Medication appeared first on Innoplexus.